CEO Focuses on Integrated Supply Growth Strategy

Edition 5 / September 2019
Editorial > 2019 Outlook: Bringing CordenPharma to the Next Level

Edition 5 / September 2019

Dr. Michael Quirmbach, Chief Executive Officer & President, CordenPharma, headshot

Author
Dr. Michael Quirmbach

Chief Executive Officer & President,
CordenPharma


2019 Outlook: Bringing CordenPharma to the Next Level

Welcome to our Q3 2019 Edition of Corden Connect. We hope you had a great summer break with family & friends and recharged your batteries for the upcoming second half of the year.

I am delighted today to write to you as the newly appointed CEO & President of CordenPharma, effective August 1, 2019. I am proud to accept this opportunity to lead the CordenPharma network and thankful to be entrusted with the responsibility of bringing our CDMO journey to the next level. With the talented and highly-motivated employees across our network based in five countries and eight manufacturing facilities, together with the support of a competent Executive Management Team, our organization is now well-positioned to serve you, our customers, in the best possible way.

Since joining CordenPharma in 2014, I have had the great opportunity to contribute to building an industry-leading Contract Development & Manufacturing Organization (CDMO). Our mission is clear: to provide superior support to leading pharmaceutical & biotechnology customers with Delivered In Full & On Time (DIFOT) products and services, keeping in mind the ultimate goal of improving the lives of the patients they serve, which are in critical need of the sophisticated medications we manufacture.

In preparation for these exciting changes, I was given the honor of attending the 2019 Advanced Management Program for Senior Executives at the Wharton School of Business in June. The program kicked off with Bill McNabb’s High-Performance Teams Exercise, where participating executives learn to row a 62-foot long, 22-inch wide racing shell together on Philadelphia’s Schuylkill River. In the weeks that followed, besides networking with an exceptional group to collaborate on many stimulating exercises, the classes with authors Nikolaj Siggelkow and Christian Terwiesch based on their book Connected Strategy provided useful insights and an eye-opening look at how CordenPharma can further develop and engage with our customers in the future.

In my new role as CEO & President, I plan to continue the growth of CordenPharma as a trusted, reliable and highly-respected CDMO by focusing on our Integrated Supply Chain Solution, supported with a clear, profitable growth strategy defined by our technology platforms. Operational excellence, transparent & cost-effective management and customer-centric focus will determine the foundation of our performance, while accelerated growth and sustained profit remain our ongoing objectives. I look forward to this challenge and anticipate a promising future for CordenPharma in the years to come.

Looking ahead, don’t forget to register soon for our September 12th webinar, which will focus on the hot topic “Navigating Injectable Combination Device & Drug Product Regulations.” Discussions on this important and rather complex pharma sector will be led by Fabio Stevanon, Global Injectables Platform Director of CordenPharma International, and Mark Chipperfield, Principal Consultant & Company Director of Corvus Device Ltd.

As always, we would be delighted to receive any feedback through your Key Account Manager on how you believe we can better serve you in the future! We look forward to a successful second half of 2019!

Dr. Michael Quirmbach
Chief Executive Officer & President,
CordenPharma


Subscribe to our Newsletter

Stay up to date with the latest thought leadership articles and news from CordenPharma.